Literature DB >> 3369137

Elucidation of alloantibodies in autoimmune haemolytic anaemia.

P James1, G P Rowe, G G Tozzo.   

Abstract

Forty-one patients with autoimmune haemolytic anaemia (AIHA), who had free antibody in their sera, were investigated for the presence of alloimmune erythrocyte antibodies using the ZZAP autoabsorption technique. Patients were subdivided into three risk categories: (I) no prior pregnancy or transfusion; (II) history of pregnancy and/or one to five transfusions; and (III) greater than 5 transfusions. A total of 13 (32%) of the 41 patients exhibited significant alloantibodies. Of 11 category-I patients 2 (18%) had significant alloantibodies. Eight (31%) of the 26 category-II patients had significant alloantibodies and 3 (75%) of the 4 category-III patients had significant alloantibodies after absorption. The majority showed Rh specificity: anti-E(8), -C(3), -Cw(1). Anti-K was found in 6 samples and 1 had anti-Fya. Alloantibodies had not been suspected prior to autoabsorption in 10 (77%) of the 13 patients with alloantibodies. These findings underline the importance of performing autoabsorption in AIHA when free autoantibody is present in the serum. Additionally, Rh phenotyping performed on ZZAP-treated cells showed complete agreement with that ascertained using pure IgM Rh typing sera and untreated cells.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3369137     DOI: 10.1111/j.1423-0410.1988.tb03893.x

Source DB:  PubMed          Journal:  Vox Sang        ISSN: 0042-9007            Impact factor:   2.144


  2 in total

1.  ACP Broadsheet No. 145: July 1995. Investigation of patients with autoimmune haemolytic anaemia and provision of blood for transfusion.

Authors:  R J Sokol; D J Booker; R Stamps
Journal:  J Clin Pathol       Date:  1995-07       Impact factor: 3.411

2.  Positive Direct Antiglobulin Test in COVID-19 patients: decision-making process.

Authors:  Julien Cabo; Alice Brochier; Pascale Saussoy; Marie-Astrid van Dievoet; Lena Capirchio; Bénédicte Delire; Véronique Deneys
Journal:  Transfus Clin Biol       Date:  2021-06-07       Impact factor: 1.406

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.